Anti-VEGF therapies effectively treat retinal disease. By blocking VEGF signaling, they target vascular permeability, angiogenesis, and inflammatory responses. The advent of anti-VEGF therapies has improved patient outcomes in neovascular age-related macular degeneration (nAMD), macular edema after retinal vein occlusion (RVO), myopic choroidal neovascularization (mCNV), and diabetic macular edema (DME). However, reference products are expensive for both patients and healthcare systems.
Biosimilars help decrease the price of these important ophthalmic agents thereby increasing access to more patients. Financial savings from biosimilars not only increase patient access but may also help improve adherence and health outcomes.
What is your clinical experience with anti-VEGF biosimilars? What considerations do you make when prescribing these agents?
-
Harpreet Walia3yrI do not see the clinical benefits that biosimilars offer to the current armamentarium of options available. -
Kendra Ott3yrI am excited to learn more about biosimilars, but I would say at this point the jury is still out. I am optimistic about advances in this field and Show More